Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 8.0% in January

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) saw a significant increase in short interest in January. As of January 15th, there was short interest totalling 5,530,000 shares, an increase of 8.0% from the December 31st total of 5,120,000 shares. Based on an average trading volume of 831,700 shares, the short-interest ratio is presently 6.6 days. Currently, 10.0% of the company’s stock are short sold.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.93% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. State Street Corp grew its stake in Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after acquiring an additional 216,484 shares in the last quarter. Erste Asset Management GmbH purchased a new position in Agios Pharmaceuticals in the 3rd quarter worth approximately $97,199,000. Geode Capital Management LLC grew its stake in Agios Pharmaceuticals by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock worth $60,326,000 after buying an additional 6,101 shares in the last quarter. Frazier Life Sciences Management L.P. grew its stake in Agios Pharmaceuticals by 19.7% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock worth $46,392,000 after buying an additional 172,180 shares in the last quarter. Finally, Fisher Asset Management LLC grew its stake in Agios Pharmaceuticals by 20.5% in the 3rd quarter. Fisher Asset Management LLC now owns 855,328 shares of the biopharmaceutical company’s stock worth $38,002,000 after buying an additional 145,416 shares in the last quarter.

Agios Pharmaceuticals Stock Performance

AGIO traded down $1.09 on Monday, reaching $33.30. The company had a trading volume of 116,041 shares, compared to its average volume of 768,897. The company’s fifty day moving average is $40.30 and its 200 day moving average is $44.36. Agios Pharmaceuticals has a fifty-two week low of $22.41 and a fifty-two week high of $62.58. The stock has a market cap of $1.90 billion, a P/E ratio of 2.93 and a beta of 0.88.

Analyst Upgrades and Downgrades

Several analysts recently commented on AGIO shares. Scotiabank upped their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. Raymond James reaffirmed an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, Royal Bank of Canada lifted their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.